Pre-Eclampsia Therapeutics Pipeline Market H2 2014 Review Report Available at RnRMarketResearch.com
Dallas, TX (PRWEB) February 20, 2015 -- The report “Pre-Eclampsia – Pipeline Review, H2 2014″ provides comprehensive information on the therapeutic development for Pre-Eclampsia. Preeclampsia is a situation that some women experience during pregnancy. The disease most usually occurs in pregnancies. Pre-eclampsia is one of the hypertensive disorders of pregnancy. The exact cause of preeclampsia is unidentified. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/pre-eclampsia-pipeline-review-h2-2014-market-report.html .
The report also reviews key players involved in the therapeutic development for pre-eclampsia and special features on late-stage and discontinued projects. Companies discussed in this Pre-Eclampsia – Pipeline Review, H2 2014 report include A1M Pharma AB, Alnylam Pharmaceuticals, Inc., Glenveigh Medical, LLC, Pluristem Therapeutics Inc., rEVO Biologics, VG Life Sciences, Inc.
The signs and symptoms of preeclampsia includes rapid weight gain, abdominal pain, severe headaches, change in reflexes, no urine output, dizziness, excessive vomiting and nausea, vision changes and shortness of breath. Drugs profile discussed in this report include ALN-AGT, Alpha-1-Microglobulin, antithrombin alfa, digoxin immune fab, Monoclonal Antibodies for Cardiovascular Diseases, Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction, Stem Cell Therapy for Pre-Eclampsia, VG-1177. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=256132 . (This is a premium report priced at US$2000 for a single user License.)
“Featured News & Press Releases cover by this report include”: Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia; Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting; Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Preeclampsia (PRESERVE-1); Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma's Treatment for Preeclampsia; Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Preeclampsia; Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Preeclampsia; Feb 20, 2014: Pluristem Submits FDA Orphan Drug Application for Preeclampsia; Nov 04, 2013: Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of content
List of Tables
Number of Products under Development for Pre-Eclampsia, H2 2014
Number of Products under Development for Pre-Eclampsia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014 15
Pre-Eclampsia - Pipeline by A1M Pharma AB, H2 2014 16
Pre-Eclampsia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014
Pre-Eclampsia - Pipeline by Glenveigh Medical, LLC, H2 2014
Pre-Eclampsia - Pipeline by Pluristem Therapeutics Inc., H2 2014
Pre-Eclampsia - Pipeline by rEVO Biologics, H2 2014
Pre-Eclampsia - Pipeline by VG Life Sciences, Inc., H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Pre-Eclampsia Therapeutics - Recent Pipeline Updates, H2 2014
Pre-Eclampsia - Dormant Projects, H2 2014
List of Figures
Number of Products under Development for Pre-Eclampsia, H2 2014
Number of Products under Development for Pre-Eclampsia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Explore more reports on Women's Health therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics .
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article